Scientific program

Thursday, November 8, 2018

 15:00 – 16:00 Opening Session Hall A
Chairperson  Jean-Pierre Pelletier, Canada
15:00 – 15:30 General Welcome
Jean-Pierre Pelletier, Canada
Johanne Martel-Pelletier, Canada
Boulos Haraoui, Canada
15:30 – 16:00 Cultural show
 16:00 – 16:10 Break
16:10 – 17:00 Asia Pacific League of Associations for Rheumatology (APLAR) Symposium:
Recent progress on genetic and cellular rheumatology in APLAR
Hall A
Speakers Huji Xu, China
Kazuhiko Yamamoto, Japan
 17:00 – 17:10 Break
 17:10 – 18:00 Industry Symposium: Understanding patient needs in the treatment of symptomatic osteoarthritis
Supported by Mylan
Hall A
Chairperson Worawit Louthrenoo, Thailand
17:10 Treatment approach for osteoarthritis: Placing patient well-being at centre stage
Jean-Pierre Pelletier, Canada
 
17:30 Evidence from clinical trials in osteoarthritis: Selecting what matters for patient care
Lucio Rovati, Italy
 
17:50 Q&A/Discussion  
 18:00 Networking Reception

Friday, November 9, 2018

08:00 – 08:50 Session:
JAK inhibitors should be first line before biologic agents
Supported by Pfizer
Hall A
Chairperson Boulos Haraoui, Canada
08:00 How to start and how taper to JAK inhibitors
Tsutomo Takeuchi, Japan
08:20 Pros and cons of JAK inhibitors over biologic DMARDs
Mark C. Genovese, USA
08:40 Discussion
 08:50 – 08:55 Break
 08:55 – 09:45 Industry Symposium: Management strategies for rheumatoid arthritis in 2018
Supported by Eli Lilly
Hall A
Chairperson Worawit Louthrenoo, Thailand  
08:55 Welcome and introduction
Worawit Louthrenoo, Thailand
 
09:00 Management strategies for rheumatoid arthritis in 2018
Tore K. Kvien, Norway
 
09:30 Q&A  
09:40 Closing remarks  
 09:45 – 10:00 Break
10:00 – 10:50 Session:
How to deal with vaccination of patients with inflammatory arthritis

Hall A
Chairperson Monika Østensen, Norway
10:00 Practical application of an immunization program in patients with inflammatory arthritis
Boulos Haraoui, Canada
10:20 Vaccination in patients with inflammatory arthritis – are they really safe?
Worawit Louthrenoo, Thailand
10:40 Discussion
 10:50 – 10:55 Break
10:55 – 11:45 Meet the Experts:
Inflammation in osteoarthritis as a therapeutic target

Hall A
Chairperson Ying Ying Katy Leung, Singapore
10:55 Inflammation in osteoarthritis. Local, systemic or both: Therapeutic implications
Johanne Martel-Pelletier, Canada
11:15 The role of matrix degradation product in the inflammation and pain in OA
Hyun Ah Kim, Korea
11:35 Discussion
 11:45 – 11:55 Break
 11:55 – 12:45 Industry Lunch Symposium: New perspectives with Diacerein
Supported by TRB
Hall A
Chairperson    
11:55 Preclinical evidence supporting the therapeutic effect of Diacerein in osteoarthritis
Johanne Martel-Pelletier, Canada
 
12:05 An international, multicentre, double-blind, randomised study of the effect of Diacerein  vs. Celecoxib in symptomatic knee osteoarthritis patients (DISSCO study)
Jean-Pierre Pelletier, Canada
 
12:20 Diacerein as an adjunct to methotrexate in the treatment of rheumatoid arthritis: Results of a multicentre, double-blind, randomized, placebo-controlled trial
Worawit Louthrenoo, Thailand
 
12:35 Q&A/Discussion  
 12:45 – 12:55 Break
12:55 – 13:45 Meet the Experts:
How to best manage osteoporosis in patients with arthritis

Hall A
Chairperson Yeong-Wook Song, Korea
12:55 Risk factors for osteoporosis in patients with arthritis
Swan Sim Yeap, Malaysia
13:15 Treatment of glucocorticoid-induced osteoporosis
Graeme Jones, Australia
13:35 Discussion
 13:45 – 14:00 Break
14:00 – 14:50 Session:
Osteoarthritis, a disease of the bone/subchondral bone?
Implication for treatment
Supported by Samumed
Hall A
Chairperson Graeme Jones, Australia
14:00 How to demonstrate structural modification in osteoarthritis: A clinical and regulatory struggle
Lee S. Simon, USA
14:20 Bisphosphonates in OA: What is the evidence?
Rohini Handa, India
14:40 Discussion
 14:50 – 14:55 Break
14:55 – 15:45 Session:
Biosimilars: Are rheumatologists and patients ready for transitioning patients from an originator to a biosimilar?
Hall A
Chairperson Mark C. Genovese, USA
14:55 European experience with switching from originator to biosimilar products in rheumatology
Tore Kvien, Norway
15:15 The impact of biosimilars in the treatment of rheumatoid arthritis: Similarities and differences of biosimilars compared to original biologics
Yeong-Wook Song, Korea
15:35 Discussion
 15:45 – 16:00 Break
 16:00 – 16:50 Industry Symposium: Biosimilar infliximab in rheumatology: Switching from originator to biosimilar based on clinical and pharmacoeconomic data
Supported by Celltrion
Hall A
Chairperson Tore K. Kvien, Norway  
16:00 Welcome and introduction: Biosimilar
Tore K. Kvien, Norway
 
16:10 Switching from originator to biosimilar infliximab: Clinical data in RA & real world data
TBA
 
16:30 Expanding access to treatment: Pharmacoeconomic of biosimilar infliximab
Michael L. Tee, Philippines
 
 16:50 – 16:55 Break
 16:55 – 17:55 Guided Poster Tour
Supported by Samumed
Chairpersons Mohit Kapoor, Canada
Chak-Sing Lau, Hong Kong

Saturday, November 10, 2018

08:00 – 08:50 Session:
Management of challenging osteoarthritis cases in daily practice: Well-kept secrets
Hall A
Chairperson Hyun Ah Kim, Korea
08:00 What to do when nothing really works ? A Canadian approach
Jean-Pierre Raynauld, Canada
08:20 Treatment of osteoarthritis: An Australian perspective
Graeme Jones, Australia
08:40 Discussion
 08:50 – 08:55 Break
08:55 – 09:45 Session:
When is biologic monotherapy the treatment of choice?
Hall A
Chairperson Lee S. Simon, USA
08:55 Biologic monotherapy is rarely the treatment of choice
Kevin Pile, Australia
09:15 The benefit and timing of biologic monotherapy
Tsutomu Takeuchi, Japan
09:35 Discussion
 09:45 – 10:00 Break
10:00 – 10:50 Session:
Novel therapeutic targets and cellular therapies for osteoarthritis

Supported by ORLIFE Pharmaceuticals – a MEDIPOST Company
Hall A
Chairperson Johanne Martel-Pelletier, Canada
10:00 Emerging therapeutic avenues in osteoarthritis
Mohit Kapoor, Canada
10:20 TBA
10:40 Discussion
 10:50 – 10:55 Break
10:55 – 11:45 Session:
Psoriatic arthritis: How to balance management of the skin and the joints
Hall A
Chairperson Kevin Pile, Australia
10:55 Diagnosis and management of psoriatic disease: A domain-based approach
Christopher T. Ritchlin, USA
11:15 Evolving therapies of psoriasis
Paulo Lorenzo, Philippines
11:35 Discussion
 11:45 – 13:00 Lunch Break and Poster Viewing
13:00 – 13:50 Meet the Experts:
Non-radiographic spondyloarthropathy: If you were paying for it, would you commence biologic therapy?
Hall A
Chairperson Christopher T. Ritchlin, USA
13:00 Nigil Haroon, Canada
13:20 The purpose of treating non-radiographic spondyloarthropathy, structure preservation
or function restoration? Is it cost-effective when using biologic therapy?
Wen Chan Tsai, Taiwan
13:40 Discussion
 13:50 – 13:55 Break
13:55 – 14:45 Session:
Intraarticular therapy for arthritis: Interesting new findings for patients
Supported by Sanofi
Hall A
Chairperson Jean-Pierre Pelletier, Canada
13:55 Viscosupplementation: What have we learned from 25 years of experience?
Jean-Pierre Raynauld, Canada
14:15 Intraarticular corticosteroid and newbies
Ying Ying Katy Leung, Singapore
14:35 Discussion
 14:45 – 15:00 Break
15:00 – 15:50 Meet the Experts:
Lupus and pregnancy: Good news for the doctor and the mother
Hall A
Chairperson Swan Sim Yeap, Malaysia
15:00 Treatment challenges in lupus pregnancy
Monika Østensen, Norway
15:20 Improving outcomes of lupus related recurrent abortion
Chak-Sing Lau, Hong Kong
15:40 Discussion
 15:50 – 15:55 Break
15:55 – 16:25 Oral Abstracts and Award Presentations
Hall A
Chairperson Johanne Martel-Pelletier, Canada
Boulos Haraoui, Canada
15:55 Presentation to Abstract Awardees
16:00 Best Abstract 1
16:10 Best Abstract 2
16:20 Questions